On the public citation graph

Screening for Advanced Liver Fibrosis Due to MASLD with VCTE Alongside Retina Scanning in Patients with Type 2 Diabetes: A Cross-Sectional Study of 1,005 Patients

0 signed · 33 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/hep.23425openalex-snapshot
Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations
inferredcites →https://doi.org/10.1002/hep.25993openalex-snapshot
Determination of reliability criteria for liver stiffness evaluation by transient elastography
inferredcites →https://doi.org/10.1016/j.cgh.2023.04.015openalex-snapshot
The Global Burden of Liver Disease
inferredcites →https://doi.org/10.1016/j.cgh.2023.12.018openalex-snapshot
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals
inferredcites →https://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferredcites →https://doi.org/10.1016/j.eprac.2022.08.002openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
inferredcites →https://doi.org/10.1016/j.forsciint.2021.111147openalex-snapshot
Investigating the use of PEth, CDT and MCV to evaluate alcohol consumption in a cohort of homeless individuals– A comparison of different alcohol biomarkers
inferredcites →https://doi.org/10.1016/j.jhep.2015.11.004openalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2016.12.022openalex-snapshot
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
inferredcites →https://doi.org/10.1016/j.jhep.2017.07.027openalex-snapshot
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
inferredcites →https://doi.org/10.1016/j.jhep.2020.06.007openalex-snapshot
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2020.11.050openalex-snapshot
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2021.05.025openalex-snapshot
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
inferredcites →https://doi.org/10.1016/j.jhep.2021.12.031openalex-snapshot
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events
inferredcites →https://doi.org/10.1016/j.jhep.2022.11.010openalex-snapshot
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
inferredcites →https://doi.org/10.1016/j.jhep.2023.06.003openalex-snapshot
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
inferredcites →https://doi.org/10.1016/s0161-6420(99)90525-0openalex-snapshot
Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study11The authors have no proprietary interest in the equipment and techniques described in this article.
inferredcites →https://doi.org/10.1016/s2213-8587(22)00003-1openalex-snapshot
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
inferredcites →https://doi.org/10.1016/s2468-1253(23)00270-4openalex-snapshot
Implementation of a liver health check in people with type 2 diabetes
inferredcites →https://doi.org/10.1034/j.1600-0420.2000.078004374.xopenalex-snapshot
Screening and prevention of diabetic blindness
inferredcites →https://doi.org/10.1053/j.gastro.2018.12.036openalex-snapshot
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2019.01.042openalex-snapshot
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2023.06.013openalex-snapshot
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
inferredcites →https://doi.org/10.1056/nejmoa2309000openalex-snapshot
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
inferredcites →https://doi.org/10.1093/alcalc/ags065openalex-snapshot
Monitoring of the Alcohol Biomarkers PEth, CDT and EtG/EtS in an Outpatient Treatment Setting
inferredcites →https://doi.org/10.1097/hep.0000000000000004openalex-snapshot
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
inferredcites →https://doi.org/10.1097/hep.0000000000000670openalex-snapshot
Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1111/j.1530-0277.2012.01737.xopenalex-snapshot
Rapid Decline of Liver Stiffness Following Alcohol Withdrawal in Heavy Drinkers
inferredcites →https://doi.org/10.1111/liv.13481openalex-snapshot
Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshot
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1136/gutjnl-2023-330110openalex-snapshot
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
inferredcites →https://doi.org/10.2337/dc20-1997openalex-snapshot
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
inferredcites →https://doi.org/10.2337/dc22-2048openalex-snapshot
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.